Table 1.
C2GnT-1 expression and clinical stage
| Clinical stage3 | ||||||
|---|---|---|---|---|---|---|
| N | Age | I | II | III | p value | |
| All | 130 | 31.8 ± 10.1 | 71 | 26 | 33 | |
| Semnoma | 65 | 34.3 ± 8.23 | 43 | 13 | 9 | |
| Relapsed/died | 7/0 | 0/0 | 4/2 | |||
| C2GnT-1 positive/all (%) | 12/43 (28) | 8/13 (62) | 8/9 (89) | 0.0012 | ||
| NSGCT1 | 65 | 29.4 ± 11.1 | 28 | 13 | 24 | |
| Embryonal carcinoma | 3 | 2 | 7 | |||
| Yolk sac carcinoma | 2 | 1 | 0 | |||
| Choriocarcinoma | 0 | 0 | 1 | |||
| Mixed | 18 | 8 | 15 | |||
| Relapsed/died | 9/0 | 2/1 | 10/7 | |||
| C2GnT-1 positive/all (%) | 9/28 (28) | 13/13 (100) | 21/24 (88) | 0.0012 | ||
1
Non-seminomatous germ cell tumor.
2
Statistical significance between stage I and II + III.
3
AJCC 6, American Joint Committee on Cancer, 6th edition, 2002.